Tvardi Therapeutics (NASDAQ:TVRD) Stock Bumped Up to “Sell” by Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a strong sell rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other brokerages have also recently issued reports on TVRD. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a report on Wednesday, July 8th. BTIG Research dropped their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a report on Wednesday, July 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, October 2nd. Finally, Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.40.

Tvardi Therapeutics Stock Down 3.3%

Shares of NASDAQ:TVRD opened at $0.94 on Friday. Tvardi Therapeutics has a 12-month low of $0.92 and a 12-month high of $5.69. The stock has a market cap of $12.54 million, a PE ratio of -0.34 and a beta of 0.38. The business has a 50 day moving average of $1.48 and a 200-day moving average of $2.41.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities research analysts expect that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

Large investors have recently modified their holdings of the company. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics in the 2nd quarter worth about $63,000. BlackRock Inc. acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at about $181,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at about $34,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.